[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-failure-with-decompensation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-failure-with-decompensation":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,80,108,138,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100491282","diuretics-alone-vs-aortix-endovascular-device-for-acute-heart-failure-100491282",false,"NCT05677100","Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure","DRAIN-HF: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure","DRAIN-HF","Inclusion Criteria (Randomized Study):\n\n* Currently admitted to the hospital with a primary diagnosis of decompensated heart failure, irrespective of ejection fraction (EF);\n* Patients should be on maximally tolerated diuretic therapy and not diuresing sufficiently before being enrolled in DRAIN-HF. After being up-titrated on diuretics, patients should be followed for at least 24 hours on the higher of: i) furosemide 80 mg IV bid or equivalent or ii) IV furosemide or equivalent IV loop diuretic at a dose 2.5 x total daily home dose of furosemide equivalents in 2 divided doses, as tolerated, patient must have: Urine Output \\\u003C1,500mL in a 12-hour period OR a Net Fluid Loss ≤375mL in a 12-hour period.\n* Persistent signs and\u002For symptoms of congestion as evidenced by at least 2+ pitting edema, elevated jugular venous pressure \\>12 cm water or ascites after treatment with IV diuretics per inclusion criterion 2.;\n* Age \\>21 years and able to provide written informed consent;\n* Negative pregnancy test if patient is of child-bearing potential.\n\nExclusion Criteria (Randomized Study):\n\n* Treatment with high dose IV inotropes within the last 48 hours prior to enrollment. High dose is defined as \\>5 µg\u002Fkg\u002Fmin dopamine OR \\>5 µg\u002Fkg\u002Fmin dobutamine OR \\>0.375 µg\u002Fkg\u002Fmin milrinone;\n* Active and ongoing hypotension with a systolic blood pressure \\\u003C90 mmHg lasting more than 30 minutes or a mean arterial pressure (MAP) \\\u003C60 mmHg lasting more than 30 minutes at enrollment;\n* Treatment with vasopressors (defined as phenylephrine, norepinephrine, epinephrine or, vasopressin) within 48 hours prior to enrollment;\n* An estimated PASP of \\>80 mmHg as measured on echocardiogram or echocardiographic evidence of primarily right heart failure;\n* Acute kidney failure defined as an increase in serum creatinine to ≥4.0mg\u002FdL (≥353.6 µmol\u002FL) at enrollment;\n* Evidence of contrast induced nephropathy, nephritis or nephrotic syndrome;\n* Prior kidney transplant, single kidney, partial nephrectomy OR use of dialysis, continuous renal replacement therapy (CRRT) or ultrafiltration in the last 90 days prior to enrollment;\n* Confirmed decompensated cirrhosis (defined as Child Pugh class B or C) or concern for shock liver (AST \\> 1000U\u002FL or total Bilirubin \\> 5.0mg\u002Fdl) at enrollment;\n* Presence of an active, uncontrolled infection that would preclude safe placement or removal of the device;\n* Prior heart transplant or likely heart transplantation before the 30- day follow-up visit;\n* Current or previous support with a durable LVAD at any time or planned LVAD insertion before the 30-day follow-up visit;\n* Use of an intra-aortic balloon pump (IABP), extracorporeal membrane oxygenation (ECMO), or percutaneous ventricular assist devices (e.g. Impella or TandemHeart) within the last 30 days;\n* Confirmed diagnosis of AL amyloidosis;\n* Acute myocardial infarction Type 1 within 30 days of enrollment, or planned coronary revascularization in the next 30 days;\n* Stroke within 30 days of enrollment;\n* Severe Bleeding Risk (any of the following):\n\n  1. Previous intracranial bleed unless there is documentation in the medical record (from a physician that is not part of the study) that the patient can safely use anticoagulation for 7 days,\n  2. GI bleeding within 6 months requiring hospitalization and\u002For transfusion,\n  3. Recent major surgery within 30 days if the surgical wound is judged to be associated with an increased risk of bleeding,\n  4. Procedure with arterial ilio-femoral access \\> 6 FR within 30 days,\n  5. Platelet count \\\u003C75,000 cells\u002Fmm3,\n  6. Uncorrectable bleeding diathesis or coagulopathy (e.g. INR ≥2 not due to anticoagulation therapy) or hypercoaguable state including HIT;\n  7. Inability to tolerate anticoagulation therapy for up to 7 days.\n* Contraindicated Anatomy :\n\n  1. Descending aortic anatomy that would prevent safe placement of the device \\[\\\u003C18 mm or \\>31 mm aorta diameter at deployment location (measured between the superior aspect of the T10 vertebra and superior aspect of the L1 vertebra)\\],\n  2. Ilio-femoral diameter or peripheral vascular anatomy that would preclude safe placement of a 21F (outer diameter) introducer sheath,\n  3. Femoral artery depth inconsistent with use of closure device,\n  4. Abnormalities or severe vascular disease that would preclude safe access and device delivery (e.g. aneurysm with thrombus, marked tortuosity, significant narrowing or inadequate size of the abdominal aorta, iliac or femoral arteries, or severe calcification),\n  5. Known connective tissue disorder (e.g. Marfan Syndrome) or other aortopathy at risk of vascular injury,\n  6. Any endovascular stent graft in the descending aorta. Any endovascular stent graft in the femoro-iliac vessels that is not well endothelialized and would preclude safe introduction\u002Fremoval of the Aortix pump as demonstrated by imaging.\n* Known hypersensitivity or contraindication to study or procedure medications (e.g. anticoagulation therapy) or device materials (e.g. history of severe reaction to nickel or nitinol);\n* Participation in any other clinical investigation that is likely to confound study results or affect the study;\n* Poor health such that the patient is unable to undergo the Aortix device placement\u002Fretrieval and\u002For unlikely to be able to survive to the 30-day visit;\n* Unable or unwilling to undergo screening (imaging, PA Catheter placement), device implant and retrieval procedures or return for 30-day visit.\n\nInclusion Criteria (Advanced Heart Failure Registry):\n\n* Currently admitted to the hospital with a primary diagnosis of decompensated HF, irrespective of ejection fraction (EF).\n* Patient has already been evaluated and indicated to receive an LVAD or heart transplant and will receive the LVAD or be listed for heart transplantation in the next 30 days if their congestion status and renal function improves.\n* Patient must have been treated with ≥ 80 mg IV furosemide bid or equivalent and have evidence of increasing diuretic dosing requirements over the past 12 months, as tolerated.\n* Must have evidence of refractoriness to medical management as documented by persistent signs and\u002For symptoms of congestion as evidenced by at least 2+ pitting edema, elevated jugular venous pressure \\>12 cm water, or ascites after treatment with IV diuretics for a minimum of 24 hours.\n* Serum creatinine ≥ 2.0 mg\u002FdL AND eGFR ≤ 45 ml\u002Fmin\u002F1.73m2 at time of enrollment\n* Age ≥ 21 years and able to provide written informed consent.\n* Negative pregnancy test if patient is of childbearing potential.\n\nExclusion Criteria (Advanced Heart Failure Registry):\n\n* Treatment with high dose IV inotropes within 48 hours prior to enrollment. High dose is defined as any one of the following: \\>5 µg\u002Fkg\u002Fmin dopamine OR \\>5 µg\u002Fkg\u002Fmin dobutamine OR \\>0.375 µg\u002Fkg\u002Fmin milrinone.\n* Active and ongoing hypotension with a systolic blood pressure \\\u003C80 mmHg lasting more than 30 minutes or a mean arterial pressure (MAP) \\\u003C55 mmHg lasting more than 30 minutes at enrollment.\n* Treatment with vasopressors (defined as phenylephrine, norepinephrine, epinephrine or, vasopressin) within 48 hours prior to enrollment.\n* An estimated PASP of \\>80 mmHg as measured on echocardiogram or echocardiographic evidence of primarily right heart failure.\n* Acute kidney failure defined as an increase in serum creatinine to ≥ 4.0mg\u002FdL at enrollment.\n* Evidence of contrast-induced nephropathy, nephritis, or nephrotic syndrome.\n* Prior kidney transplant, single kidney, partial nephrectomy OR use of dialysis, continuous renal replacement therapy (CRRT), or ultrafiltration in the last 90 days prior to enrollment.\n* Confirmed decompensated cirrhosis (defined as Child Pugh class B or C) or concern for shock liver (AST \\> 1000U\u002FL or total Bilirubin \\> 5.0mg\u002Fdl) at enrollment.\n* Presence of an active, uncontrolled infection that would preclude safe placement or removal of the device.\n* Current or previous support with a durable LVAD.\n* INTERMACS Profile 1 at enrollment.\n* Currently on mechanical ventilatory support.\n* Use of an extracorporeal membrane oxygenation (ECMO) or percutaneous ventricular assist device (e.g., Impella or TandemHeart) within the last 30 days.\n* Confirmed diagnosis of AL amyloidosis.\n* Acute myocardial infarction Type 1 within 30 days of enrollment or planned coronary revascularization in the next 30 days.\n* Stroke within 30 days of enrollment.\n* Severe Bleeding Risk (any of the following):\n\n  * Previous intracranial bleed unless there is documentation in the medical record (from a physician that is not part of the study) that the patient can safely use anticoagulation for 7 days.\n  * GI bleeding within 6 months requiring hospitalization and\u002For transfusion.\n  * Recent major surgery within 30 days if the surgical wound is judged to be associated with an increased risk of bleeding.\n  * Procedure with arterial ilio-femoral access \\> 6 Fr within 30 days.\n  * Platelet count \\\u003C75,000 cells\u002Fmm3 .\n  * Uncorrectable bleeding diathesis or coagulopathy (e.g., INR≥ 2 not due to anticoagulation therapy) or hypercoagulable state including HIT.\n  * Inability to tolerate anticoagulation therapy for up to 7 days.\n* Contraindicated Anatomy :\n\n  * Descending aortic anatomy that would prevent safe placement of the device \\[\\\u003C18 mm or \\>31 mm aorta diameter at deployment location (measured between the superior aspect of the T10 vertebra and superior aspect of the L1 vertebra)\\].\n  * Ilio-femoral diameter or peripheral vascular anatomy that would preclude safe placement of a 21 Fr (outer diameter) introducer sheath.\n  * Femoral artery depth inconsistent with use of closure device.\n  * Abnormalities or severe vascular disease that would preclude safe access and device delivery (e.g., aneurysm with thrombus; marked tortuosity; significant narrowing or inadequate size of the abdominal aorta, iliac, or femoral arteries; or severe calcification).\n  * Known connective tissue disorder (e.g., Marfan Syndrome) or other aortopathy at risk of vascular injury.\n  * Any endovascular stent graft in the descending aorta. Any endovascular stent graft in the femoro-iliac vessels that is not well endothelialized and would preclude safe introduction\u002Fremoval of the Aortix pump as demonstrated by imaging.\n* Known hypersensitivity or contraindication to study or procedure medications (e.g., anticoagulation therapy) or device materials (e.g., history of severe reaction to nickel or nitinol).\n* Participation in any other clinical investigation that is likely to confound study results or affect the study.\n* Poor health such that the patient is unable to undergo the Aortix device placement\u002Fretrieval and\u002For unlikely to be able to survive to the 30-day visit.\n* Unable or unwilling to undergo screening, device implant and retrieval procedures, or return for 30-day visit.","ALL","21 Years",{"count":20,"type":21},320,"ESTIMATED","INTERVENTIONAL",[24],"NA","Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy.\n\nEligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.",[27,28,29,30,31,32,33,34],"Heart Failure","Cardiorenal Syndrome","Cardio-Renal Syndrome","ADHF","Heart Failure, Systolic","Heart Failure, Diastolic","Heart Failure; With Decompensation","Heart Failure, Congestive",[36,37],"mechanical circulatory support","percutaneous","RECRUITING","2026-08-03",{"date":41,"type":42},"2026-08-04","ACTUAL",{"date":44,"type":42},"2023-08-23",{"date":46,"type":21},"2028-08",{"name":48,"class":49},"Procyrion","INDUSTRY",49,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100293750","biomarker-guided-discharge-of-heart-failure-patients-100293750","NCT03103932","Biomarker Guided Discharge of Heart Failure Patients","BiomarkeR cAndidates to Guide Discharge of Patients Admitted to Hospital With heARt Failure","RADAR","Inclusion Criteria:\n\n* Patients admitted to hospital with a primary diagnosis of acute decompensated heart failure, compatible with the modified Framingham criteria\n\nExclusion Criteria:\n\n* Patient unable to provide blood samples or cannot participate in follow-up\n* Patient with end stage organ failure\n\n  * Kidney: creatinine \\>350 μmol\u002FL or Estimated GFR ≤15 ml\u002Fmin\n  * Liver dysfunction: liver function test \\>2.5 times normal\n  * Lungs: pulmonary FEV1\\\u003C50% predicted\n* Patient requiring intubation\n* Patient with an admission NTproBNP measurement of \\>30,000 pg\u002Fml\n* Patient listed for heart transplant, or admitted specifically for transplant workup\n* Patient in cardiogenic shock\n* Patient with life expectancy of less than 6 months, or has major co-morbidities such as new stroke, cancer, pneumonia, or other serious life threatening illness\n* Patient with conditions that will make it difficult to discharge from hospital such as a fall or waiting for a long term care bed\n* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patient at risk because of participation in the trial, or may bias the result of the trial, or the patient's ability to participate in the trial\n* Patient who has participated in another research trial involving an investigational product in the past 30 days","18 Years",{"count":61,"type":21},750,[24],"This is a multi-centre, single blind, randomized study. Patients admitted to hospital with acute decompensated heart failure will be randomized to biomarker guided discharge algorithm vs usual care in a 2:1 ratio. NTproBNP and other biomarkers will be measured within 24 hours of admission. The NTproBNP results will be used to further stratify participants randomized to the biomarker guided group into lower and medium to higher risk pathways. Biomarkers will be repeated after 2-3 days and again prior to discharge. Specific care pathways will be followed for each of the lower risk and medium-higher risk groups. Biomarkers will be repeated 30 days post discharge. Participants will be followed with a phone call at 3 months and return for a follow up visit at 6 months post discharge for outcome evaluation.",[33],[66,67,68],"biomarkers","heart failure","hospital admission","2026-04-29",{"date":71,"type":42},"2026-05-06",{"date":73,"type":42},"2017-08-26",{"date":75,"type":21},"2026-12-30",{"name":77,"class":78},"Ottawa Heart Institute Research Corporation","OTHER",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":79},"100611934","heart-failure-management-for-patient-with-cied-remotely-monitored-100611934","NCT07247032","Heart Failure Management for Patient With CIED Remotely Monitored","Prospective Real World Heart Failure Management for Patient With CIED Remotely Monitored","PROACT-HF","Inclusion Criteria:\n\n* Patient aged 18-85\n* Patient diagnosed with a New York Heart Association (NYHA) class II or III\n* Patients with left ventricular ejection fraction ≼ 40 %\n* Patient implanted with an ICD or CRT-D (BiV and\u002For LBBA pacing) since at least 30 days and compatible with SignalHF (Biotronik, Boston Scientific and Medtronic)\n* Non-activation of others HF multisensor algorithms\n* Patient remote monitored on Implicity CIED platform\n* Patient with a documented diagnosis of heart failure, eligible to reimbursement in France or Germany for HF remote monitoring\n* Patient is willing to be remotely monitored for heart failure\n* HF treated according to European Society of Cardiology (ESC) guidelines\n\nExclusion Criteria:\n\n* Patients undergoing or awaiting heart transplant or left ventricular assist device (LVAD) procedures\n* Patients with a life expectancy of less than 12 months\n* Patients enrolled in concurrent clinical studies\n* Patients with a history of non-compliance with medical care or inability to comply with the study protocol\n* Patients already receiving remote monitoring for heart failure\n* Pregnant or breastfeeding women\n* Subjects under legal protection","85 Years",{"count":90,"type":21},1132,[24],"This randomized, controlled, open-label, parallel, multicenter clinical study evaluates the efficacy of SmartSignalHF compared with heart failure (HF) remote monitoring (RM) standard of care in implanted patients with heart failure. The primary objective is to determine whether SmartSignalHF reduces all-cause mortality and HF hospitalizations at 12 months.",[27,94,95,96,97,98],"Heart Failure NYHA Class II","Heart Failure NYHA Class III","Heart Failure With Reduced Ejection Fraction (HFrEF)","Heart Failure With Decompensation","CRT and\u002For ICD","2026-03-26",{"date":101,"type":42},"2026-03-31",{"date":103,"type":42},"2025-12-19",{"date":105,"type":21},"2027-05",{"name":107,"class":49},"Implicity",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":79},"100579078","prediction-of-heart-failure-with-machine-learning-100579078","NCT06819618","Prediction of Heart-Failure with Machine Learning","Predicting Heart Failure Recovery by Wearables and Machine Learning","PRE-HF-ML","Inclusion Criteria:\n\n* age over 17\n* HFrEF with LV-EF under 41\n* hospitalized for decompensated heart failure with a) nTproBNP over 1000 AND b) willing to participate AND c) at least one out of three clinical signs (edema, pleural effusion, ascites)\n\nExclusion Criteria:\n\n* life expectancy under 6 months due to non-cardiac conditions\n* inability to use smartwatch\n* severe valvular lesions",{"count":117,"type":21},32,"OBSERVATIONAL","In this monocentric observational study the research question is to what extent data collected via Apple Watch can predict the heart failure status of decompensated HF patients. For this purpose, physiological data from the Apple Watch (such as single-lead electrocardiogram, SpO2, respiratory rate, step count, nighttime temperature, etc.) will be extracted and used as predictor variables to forecast outcomes like risk of decompensation and rehospitalization within the follow-up period. Since this is a data-driven study, additional data collected as part of guideline-compliant treatment will also be included.",[121,27,122,123,124],"Heart Failure with Reduced Ejection Fraction","Heart Failure，Congestive","Heart Failure Acute","Heart Failure; with Decompensation",[27,126,127,128],"Wearables","Monitoring","Apple Watch","2025-02-09",{"date":131,"type":42},"2025-02-11",{"date":133,"type":42},"2024-04-01",{"date":135,"type":21},"2025-05-31",{"name":137,"class":78},"University Medical Center Goettingen",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":79},"100564572","phase-3-prevention-of-worsening-renal-function-of-intravenus-albumin-in-heart-failure-patients-100564572","NCT06630923","PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS","HUMAN ALBUMIN IN HEART FAILURE - DIORASIS TRIAL","Inclusion Criteria:\n\n1. age over 18 yrs\n2. acute decompensation of CHF\n3. evidence of hepatic dysfunction by laboratory biochemical measurements or imaging (liver ultrasonography)\n4. history of CHF with previous use of an oral loop diuretic\n5. anticipated need for IV diuretic therapy for at least 72 hours\n\nThere is no pre-specified inclusion criterion with respect to ejection fraction\n\nExclusion Criteria:\n\n1. hemodynamic collapse (at least one of the following: systolic blood pressure (BP) \\\u003C 90 mmHg, or BP drop by \\>= 40 mmHg for \\>= 15 min, with end-organ hypoperfusion; need for inotropes (except of digoxin); need for cardiopulmonary resuscitation).\n2. hepatic dysfunction of other than cardiac etiology\n3. severe anemia (Hb\\\u003C8 g\u002FdL)\n4. uncontrolled hypertension or hypertensive emergency\u002Furgency\n5. pulmonary edema or pulmonary congestion necessitating use of IV vasodilators\n6. serum creatinine \\> 3 mg\u002FdL or glomerular filtration rate (GFR) \\\u003C 30 ml\u002Fmin","95 Years",{"count":147,"type":21},250,[149],"PHASE3","Patients hospitalized for acute decompensation of CHF are usually complicated by worsening renal function (WRF) which leads to diuretic resistance and inadequate decongestion as well as poor prognosis. WRF has been attributed to a reflex renal vasoconstriction elicited by intravascular volume depletion during brisk diuresis. The investigators hypothesize that CHF patients with hepatic dysfunction are more prone to WRF due to poor albumin production. This sub-group of CHF patients may benefit more (increased diuretic efficacy and protected against worsening renal function) by the use of IV loop diuretics in combination with an intravascular volume expander such as IV Human Albumin.",[152,33,153],"Diuretics Drug Reactions","Albumin; Double",[155,156,27],"Human Albumin","Furosemide","2024-10-04",{"date":159,"type":42},"2024-10-08",{"date":161,"type":42},"2023-01-14",{"date":163,"type":21},"2026-12-11",{"name":165,"class":78},"Democritus University of Thrace",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":79},"100477562","targeting-loxl2-and-cardiac-fibrosis-for-post-acute-heart-failure-treatment--a-prospective-study-100477562","NCT05498584","Targeting LOXL2 and Cardiac Fibrosis for Post-acute Heart Failure Treatment- A Prospective Study","Inclusion Criteria:\n\n1. Patients must give written informed consent before any assessment is performed.\n2. Inpatients \\>= 20 years of age, male or female.\n3. Patients with a diagnosis of heart failure New York Heart Association (NYHA) class II-IV with BNP \\>=100 pg\u002FmL or NT-porBNP \\>= 400 pg\u002FmL ( \\>= 900 pg\u002FmL if concomitant atrial fibrillation)\n4. Left ventricular ejection fraction \\\u003C= 40% by echocardiography or other methods\n\nExclusion Criteria:\n\n1. Estimated survival time \\\u003C 6 months\n2. Long-term bedridden for more than 3 months\n3. Cannot tolerate exercise test due to muscular skeletal disorder.\n4. Cannot cooperate all functional studies\n5. Ventilator dependent\n6. Terminal heart status\n7. Family rejects to participate in this project\n8. Primary severe valvular heart disease","20 Years","100 Years",{"count":175,"type":21},130,"A previous study demonstrated that a multidisciplinary cardiac rehabilitation (CR) program was associated with reduced medium- to long-term all-cause mortality in a retrospective propensity score-matched study. The investigators will further investigate the predictors including LOXl2, cardiac MRI, and endothelial function that will benefit from a successful CR.",[33],[67,179,180,181,182,183],"cardiac fibrosis","cardiac rehabilitation","endothelial function","cardiopulmonary exercise test","cardiac MRI","2024-07-15",{"date":186,"type":42},"2024-07-16",{"date":188,"type":42},"2022-08-25",{"date":190,"type":21},"2026-08-30",{"name":192,"class":78},"Chang Gung Memorial Hospital"]